Nearly of Americans are living with overweight or obesity, and therefore at higher risk for chronic and debilitating conditions such as diabetes and heart disease. , such as Ozempic and Wegoby, which help people lose weight by reducing their appetite and altering their digestion, have been hailed as a miracle with the potential to transform health and reduce costs at the national level. They may also support heart and kidney health.
Demand for GLP-1s is huge and growing, but access is uneven. These drugs can be expensive, topping $1,000 per month without insurance. On the other hand, less expensive options are readily available through loosely regulated direct-to-consumer telehealth companies, raising quality and safety concerns. Although around of Americans say they have taken a GLP-1 at one time or another, the long-term effects of using these drugs as well as the health impacts of discontinuing use are not well known.泭
What should patients, physicians, insurers, policy makers, and researchers know about GLP-1 cost, access, and safety? This timely conversation and expert Q&A will be valuable to anyone with a personal or professional interest in these powerful new drugs.
Agenda
Additional speakers to be announced. Agenda is subject to change.
3:00 pm | Welcome
3:05 | Discussion
- (Moderator), Former Secretary, U.S. Department of Health & Human Services
- , Medical Director, Weight Wellness Program, UT Southwestern Medical Center
- , Associate Professor of Law, University of Colorado Law School
- , Senior Fellow, Cato Institute
- , Director, Policy Strategy & Alliances, Obesity Action Coalition
3:50 | Audience Q&A
4:25 | Closing Remarks
4:30 | Adjourn
Health in the Headlines
This event is part of the 做厙TV’s Health in the Headlines series, which investigates high-profile health and health policy topics making the news. Co-chaired by Alex Azar, former HHS Secretary, and Megan Ranney, Dean of the Yale School of Public Health, the series creates space for nuanced discussion and respectful debate among a diverse set of experts. Series guests are encouraged to distinguish clearly between empirical evidence and personal, cultural, or policy values that may shape their interpretation of the science.
